CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection

Clinical Immunology

Volumn 102, Issue 2, 2002, Pages 154-161

  Lange, Christoph G ^a   Valdez, Hernan ^a   Medvik, Kathy ^a   Asaad, Robert ^a   Lederman, Michael M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

AIDS; CD4+ nadir; HAART; HIV; HIV p24; Immune restoration; Lymphocyte proliferative responses

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; POKEWEED MITOGEN; STREPTOKINASE; TETANUS TOXOID;

ADULT; ARTICLE; CANDIDA ALBICANS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MYCOBACTERIUM AVIUM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0036179384     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5164     Document Type: Article

References (40)

1. Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease
2. Immune restoration with antiretroviral therapies: Implications for clinical management
3. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: Age inversely predicts naive CD 4 cell count increase
4. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen
5. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy
6. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years
7. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection
8. + T cell homeostasis and function in advanced HIV disease
9. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
10. + T lymphocytes
11. + T cell responses associated with control of viremia
12. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1
13. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
14. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
15. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
16. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
17. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease
18. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
19. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution
20. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression
21. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir
22. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology study group of Spanish EARTH-1 study
23. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection
24. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
25. Virological and immunological responses to HAAT in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count
26. Discordant CD4/RNA responses to HAAT are strongly associated with high baseline CD4 count and low HIV RNA: Analysis of 406 naive patients
27. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection
28. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
29. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy
30. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy: The Swiss HIV Cohort Study
31. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy: Swiss HIV Cohort Study
32. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
33. HIV-1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses
34. Lymphocyte proliferation assays may underestimate antigen responsiveness in human immunodeficiency virus infection
35. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-1 infected patients
36. + T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy
37. + T cells persist, but proliferation is suppressed during high-level HIV-1 viremia
38. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation